The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

Biolinq received $100 million in a Series C funding round to bring its wearable for patients with diabetes to market, the ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 with ...

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

Science Connected Magazine is an editorially independent, non-profit newsroom producing open-access science journalism and ...

Abbott is already a big player in the wearable ... glucose-monitoring sector, and has started working on a new device that will measure both glucose and ketones, potentially serving as a warning ...

RSP Systems is developing the first non-invasive glucose monitoring wearable for people needing to monitor their blood-sugar levels. Its proprietary technology, GlucoBeam Smart™, is based on ...

“By listening to the needs of our users, we’re proud to offer the longest lasting wearable and most accurate CGM, giving people the knowledge to better control their diabetes with our best-in ...

The U.S. Food and Drug Administration approved DexCom, Inc.’s (NASDAQ:DXCM) Dexcom G7 15-Day Continuous Glucose Monitoring System for people over 18 with diabetes. With an overall Mean Absolute ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System for people over the age of 18 ...